Mallinckrodt plc (MNK) dropped -0.12% or -0.06 points to trade at $48.67 per share. As per the latest trading data available, the net money flow stood at $0.93 million as the shares received $1.46 million in upticks and gave away $0.53 million in downticks. The final up/down ratio was at 2.74. On a weekly basis, the stock has seen a change of 3.4%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 0. $0.98 million was the inflow in upticks and $0 million was the outflow in downticks. For the block trade, the net money flow was $0.98 million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Mallinckrodt Public Limited Company appreciated by 4.03% during the last five trading days but lost 1.67% on a 4-week basis. Mallinckrodt Public Limited Company has dropped 17.33% during the last 3-month period . Year-to-Date the stock performance stands at -1.67%. Mallinckrodt plc (NYSE:MNK) rose 0.53% or 0.26 points on Wednesday and made its way into the gainers of the day. After trading began at $48.93 the stock was seen hitting $49.03 as a peak level and $47.52 as the lowest level. The stock ended up at $48.99. The daily volume was measured at 1,888,831 shares. The 52-week high of the share price is $85.83 and the 52-week low is $42.6701. The company has a market cap of $5,133 million.
Company has reported several Insider transactions to the SEC, on May 11, 2016, Matthew K Harbaugh (CFO) purchased 500 shares at 59.37 per share price.On May 10, 2016, Hugh M. Oneill (Sr. VP & Pres, ARD) purchased 1,653 shares at 60.99 per share price.On May 9, 2016, Steven J. Romano (Sr. VP & Chief Scientific Ofcr) purchased 900 shares at 56.00 per share price.
Mallinckrodt PLC Last issued its quarterly earnings results on Nov 29, 2016. The company reported $2.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.05. Analyst had a consensus of $1.99. The company had revenue of $887.20 million for the quarter, compared to analysts expectations of $875.68 million. The companys revenue was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Mallinckrodt PLC was Resumed by Oppenheimer to Outperform on Dec 7, 2016. Mallinckrodt PLC was Reiterated by Mizuho on Nov 30, 2016 to Buy, Lowers Price Target to $ 85 from a previous price target of $87 .Mallinckrodt PLC was Reiterated by Mizuho on Nov 23, 2016 to Buy, Lowers Price Target to $ 87 from a previous price target of $89 .Mallinckrodt PLC was Initiated by Raymond James to Outperform on Nov 18, 2016.
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The companys Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.